A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy

Shi, Jinjin; Liu, Yan; Wang, Lei; Gao, Jun; Zhang, Jing; Yu, Xiaoyuan; Ma, Rou; Liu, Ruiyuan; Zhang, Zhenzhong

doi:10.1016/j.actbio.2013.10.037

Cited by 121 publications

(74 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the treatment based on single chemo-13 therapy is unsatisfied due to the emergency of multidrug 14 resistance (MDR) (MacDiarmid et al, 2009;Nagasubramanian 15 et al, 2003). To improve therapeutic efficiency and minimize side 16 effect, various combined treatments have been explored 17 (e.g., thermo-chemotherapy, chemo-photodynamic therapy, che-18 mo-sonodynamic therapy) (Gong et al, 2013;Lin et al, 2014;Park 19 et al, 2009;Shi et al, 2014;Yang et al, 2013). The combination of 20 chemotherapy with other therapeutic approaches has been 21 demonstrated to generate synergistic antitumor effect, resulting 22 in lower doses of therapeutic agent and side effects (Park et al,23 2009; You et al, 2010).…”

mentioning

confidence: 97%

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

Shen

Liu

et al. 2015

International Journal of Pharmaceutics

147

View full text Add to dashboard Cite

mentioning

confidence: 97%

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

Shen

Liu

et al. 2015

International Journal of Pharmaceutics

147

View full text Add to dashboard Cite

“…Compared to monotherapy, NCP@pyrolipid exhibited superior efficacy in a cisplatin-resistant human head and neck cancer SQ20B xenograft murine model. DOX was conjugated with PEI-derivatized fullerene via a pHsensitive hydrazone linkage, and resulting C 60 -PEI-DOX [241] exhibited selective accumulation of DOX in the tumor and a synergistic antitumor efficacy with photodynamic therapy in an animal tumor model after intravenous injection. Diadduct malonic acid-fullerene (DMA-C 60 )-and DTX-encapsulating mPEG-PCL micelles (DMA-C 60 /DTX) [242] showed sustained release of the payloads and subsequently generated ROS in cancer cells upon irradiation with 532 nm light.…”

Section: Combined Photodynamic and Chemotherapymentioning

confidence: 99%

“…6. Nanocarriers combine chemotherapy with physically destructive modalities that induce tumor ablation (photothermal/magnetic) [218][219][220][221][222][223][224][225][226][227][228][229][230][231][232][233][234][235][236]245,246], generate reactive oxygen species (photodynamic) [232][233][234][235][236][237][238][239][240][241][242], and form of free radicals (radiotherapy) to maximize cancer eradication [243]. [246] and demonstrated higher anticancer activity in vitro and in vivo than PTX/PLGA/HAuNPs microspheres alone (no NIR-irradiation) or PLGA/HAuNPs microspheres (no PTX) with NIR irradiation.…”

Section: Combined Photothermal and Chemotherapymentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

423

258

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oThe dynamic and versatile nature of diseases such as cancer has been a pivotal challenge for developing efficient and safe therapies. Cancer treatments using a single therapeutic agent often result in limited clinical outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple therapeutic modalities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing side effects. Co-administration of multiple therapeutic agents requires a delivery platform that can normalize pharmacokinetics and pharmacodynamics of the agents, prolong circulation, selectively accumulate, specifically bind to the target, and enable controlled release in target site. Nanomaterials, such as polymeric nanoparticles, gold nanoparticles/cages/shells, and carbon nanomaterials, have the desired properties, and they can mediate therapeutic effects different from those generated by small molecule drugs (e.g., gene therapy, photothermal therapy, photodynamic therapy, and radiotherapy). This review aims to provide an overview of developing multi-modal therapies using nanomaterials ("combo" nanomedicine) along with the rationale, up-to-date progress, further considerations, and the crucial roles of interdisciplinary approaches.

show abstract

“…The HP conjugates were first synthesized by the reaction of amino group on PEI with the carboxylic group on HBA through amidocarbonylation reactions. 30 The 1 H NMR spectra of HP and DNP in D 2 O were as shown in Figures 1A and B. The successful conjugation of HBA to PEI was confirmed by the appearance of chemical shifts at 7.0-8.0 ppm for the aromatic protons of HBA.…”

Section: Results and Discussion Synthesis Of Hp And Dhpmentioning

confidence: 78%

Tumor microenvironment dual-responsive core–shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA

Wang¹,

Yu²,

Han³

et al. 2017

IJN

View full text Add to dashboard Cite

As the tumor microenvironment (TME) develops, it is critical to take the alterations of pH value, reduction and various enzymes of the TME into consideration when constructing the desirable co-delivery systems. Herein, TME pH and enzyme dual-responsive core–shell nanoparticles were prepared for the efficient co-delivery of chemotherapy drug and plasmid DNA (pDNA). A novel pH-responsive, positively charged drug loading material, doxorubicin (DOX)-4-hydrazinobenzoic acid (HBA)-polyethyleneimine (PEI) conjugate (DOX-HBA-PEI, DHP), was synthesized to fabricate positively charged polyion complex inner core DHP/DNA nanoparticles (DDN). Hyaluronic acid (HA) was an enzyme-responsive shell which could protect the core and enhance the co-delivery efficiency through CD44-mediated endocytosis. The HA-shielded pH and enzyme dual-responsive nanoparticles (HDDN) were spherical with narrow distribution. The particle size of HDDN was 148.3±3.88 nm and the zeta potential was changed to negative (−18.1±2.03 mV), which led to decreased cytotoxicity. The cumulative release of DOX from DHP at pH 5.0 (66.4%) was higher than that at pH 7.4 (30.1%), which indicated the pH sensitivity of DHP. The transfection efficiency of HDDN in 10% serum was equal to that in the absence of serum, while the transfection of DDN was significantly decreased in the presence of 10% serum. Furthermore, cellular uptake studies and co-localization assay showed that HDDN were internalized effectively through CD44-mediated endocytosis in the tumor cells. The efficient co-delivery of DOX and pEGFP was confirmed by fluorescent image taken by laser confocal microscope. It can be concluded that TME dual-responsive HA-shielded core–shell nanoparticles could be considered as a promising platform for the co-delivery of chemotherapy drug and pDNA.

show abstract

A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy

Cited by 121 publications

References 45 publications

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Tumor microenvironment dual-responsive core–shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA

Contact Info

Product

Resources

About

A tumoral acidic pH-responsive drug delivery system based on a novel photosensitizer (fullerene) for in vitro and in vivo chemo-photodynamic therapy

Cited by 121 publications

References 45 publications

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

Core–shell structured Fe3O4@TiO2-doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Tumor microenvironment dual-responsive core&ndash;shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA

Contact Info

Product

Resources

About

Tumor microenvironment dual-responsive core–shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA